Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Cardiotoxicity 1

Interventions

Echocardiography 4Electrocardiography 2sulforaphane 1schizandrin 1sacubitril and valsartan sodium hydrate drug combination 1pegfilgrastim 1nicotinamide-beta-riboside 1fructus schizandrae, radix ginseng, radix ophiopogonis drug combination 1empagliflozin 1Watchful Waiting 1Vincristine 1Tablets 1Rituximab 1Proton Therapy 1Proteins 1Prednisolone 1Observation 1Medical History Taking 1Lenalidomide 1Laser-Doppler Flowmetry 1Exercise 1Environmental Biomarkers 1Echocardiography, Stress 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Clinical Laboratory Techniques 1Chemoradiotherapy 1Carvedilol 1Blood Pressure Determination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cardiotoxicity × schizandrin × Clear all
NCT06214195 2024-01-19

START

Zhejiang Cancer Hospital

Phase 3 Recruiting
276 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡